1
|
Mydlo JH: Growth factors and renal cancer:
Characterization and therapeutic implications. World J Urol.
13:356–363. 1995. View Article : Google Scholar : PubMed/NCBI
|
2
|
Cohen HT and McGovern FJ: Renal-cell
carcinoma. N Engl J Med. 353:2477–2490. 2005. View Article : Google Scholar : PubMed/NCBI
|
3
|
Dutcher JP, Mourad WF and Ennis RD:
Integrating innovative therapeutic strategies into the management
of renal cell carcinoma. Oncology. 26:526–530.
5325342012.PubMed/NCBI
|
4
|
Shablak A, Hawkins RE, Rothwell DG and
Elkord E: T cell-based immunotherapy of metastatic renal cell
carcinoma: Modest success and future perspective. Clin Cancer Res.
15:6503–6510. 2009. View Article : Google Scholar : PubMed/NCBI
|
5
|
Pate PH, Chaganti RSK and Motzer RJ:
Target therapy for meta-static renal cell carcinoma. Br J Cancer.
94:914–919. 2006.
|
6
|
Singer EA, Gupta GN and Srinivasan R:
Update on targeted therapies for clear cell renal cell carcinoma.
Curr Opin Oncol. 23:283–289. 2011. View Article : Google Scholar : PubMed/NCBI
|
7
|
Finke J, Kierstead LS, Ranieri E and
Storkus WJ: Immunologic response to RCC. Renal Cell Carcinoma:
Molecular Biology, Immunology and Clinical Management. Bukowski RM
and Novick AC: Humana Press; pp. 39–62. 2000, View Article : Google Scholar
|
8
|
McDermott DF: Immunotherapy of metastatic
renal cell carcinoma. Cancer. 115(Suppl): 2298–2305. 2009.
View Article : Google Scholar : PubMed/NCBI
|
9
|
Fregni G, Perier A, Pittari G, Jacobelli
S, Sastre X, Gervois N, Allard M, Bercovici N, Avril MF and
Caignard A: Unique functional status of natural killer cells in
metastatic stage IV melanoma patients and its modulation by
chemotherapy. Clin Cancer Res. 17:2628–2637. 2011. View Article : Google Scholar : PubMed/NCBI
|
10
|
Ward DG, Cheng Y, N'Kontchou G, Thar TT,
Barget N, Wei W, Billingham LJ, Martin A, Beaugrand M and Johnson
PJ: Changes in the serum proteome associated with the development
of hepatocellular carcinoma in hepatitis C-related cirrhosis. Br J
Cancer. 94:287–292. 2006. View Article : Google Scholar : PubMed/NCBI
|
11
|
Adam BL, Qu Y, Davis JW, Ward MD, Clements
MA, Cazares LH, Semmes OJ, Schellhammer PF, Yasui Y, Feng Z, et al:
Serum protein fingerprinting coupled with a pattern-matching
algorithm distinguishes prostate cancer from benign prostate
hyperplasia and healthy men. Cancer Res. 62:3609–3614.
2002.PubMed/NCBI
|
12
|
Pawlik TM, Hawke DH, Liu Y, Krishnamurthy
S, Fritsche H, Hunt KK and Kuerer HM: Proteomic analysis of nipple
aspirate fluid from women with early-stage breast cancer using
isotope-coded affinity tags and tandem mass spectrometry reveals
differential expression of vitamin D binding protein. BMC Cancer.
6:682006. View Article : Google Scholar : PubMed/NCBI
|
13
|
Li J, Zhang Z, Rosenzweig J, Wang YY and
Chan DW: Proteomics and bioinformatics approaches for
identification of serum bio-markers to detect breast cancer. Clin
Chem. 48:1296–1304. 2002.PubMed/NCBI
|
14
|
Mueller J, von Eggeling F, Driesch D,
Schubert J, Melle C and Junker K: ProteinChip technology reveals
distinctive protein expression profiles in the urine of bladder
cancer patients. Eur Urol. 47:885–893; discussion 893–894. 2005.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Chen YD, Zheng S, Yu JK and Hu X:
Artificial neural networks analysis of surface-enhanced laser
desorption/ionization mass spectra of serum protein pattern
distinguishes colorectal cancer from healthy population. Clin
Cancer Res. 10:8380–8385. 2004. View Article : Google Scholar : PubMed/NCBI
|
16
|
Poon TC, Sung JJ, Chow SM, Ng EK, Yu AC,
Chu ES, Hui AM and Leung WK: Diagnosis of gastric cancer by serum
proteomic fingerprinting. Gastroenterology. 130:1858–1864. 2006.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Yang SY, Xiao XY, Zhang WG, Zhang LJ,
Zhang W, Zhou B, Chen G and He DC: Application of serum SELDI
proteomic patterns in diagnosis of lung cancer. BMC Cancer.
5:832005. View Article : Google Scholar : PubMed/NCBI
|
18
|
Zhang Z, Bast RC Jr, Yu Y, Li J, Sokoll
LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang YY, Meng XY, et al:
Three biomarkers identified from serum proteomic analysis for the
detection of early stage ovarian cancer. Cancer Res. 64:5882–5890.
2004. View Article : Google Scholar : PubMed/NCBI
|
19
|
Raimondo F, Salemi C, Chinello C,
Fumagalli D, Morosi L, Rocco F, Ferrero S, Perego R, Bianchi C,
Sarto C, et al: Proteomic analysis in clear cell renal cell
carcinoma: Identification of differentially expressed protein by
2-D DIGE. Mol Biosyst. 8:1040–1051. 2012. View Article : Google Scholar : PubMed/NCBI
|
20
|
Valera VA, Li-Ning-T E, Walter BA, Roberts
DD, Linehan WM and Merino MJ: Protein expression profiling in the
spectrum of renal cell carcinomas. J Cancer. 1:184–196. 2010.
View Article : Google Scholar : PubMed/NCBI
|
21
|
Sun CY, Zang YC, San YX, Sun W and Zhang
L: Proteomic analysis of clear cell renal cell carcinoma.
Identification of potential tumor markers. Saudi Med J. 31:525–532.
2010.PubMed/NCBI
|
22
|
Fuhrman SA, Lasky LC and Limas C:
Prognostic significance of morphologic parameters in renal cell
carcinoma. Am J Surg Pathol. 6:655–663. 1982. View Article : Google Scholar : PubMed/NCBI
|
23
|
Kausche S, Wehler T, Schnürer E, Lennerz
V, Brenner W, Melchior S, Gröne M, Nonn M, Strand S, Meyer R, et
al: Superior antitumor in vitro responses of allogeneic matched
sibling compared with autologous patient CD8+ T cells.
Cancer Res. 66:11447–11454. 2006. View Article : Google Scholar : PubMed/NCBI
|
24
|
Boland CR, Thibodeau SN, Hamilton SR,
Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA,
Fodde R, Ranzani GN, et al: A National Cancer Institute Workshop on
Microsatellite Instability for cancer detection and familial
predisposition: Development of international criteria for the
determination of microsatellite instability in colorectal cancer.
Cancer Res. 58:5248–5257. 1998.PubMed/NCBI
|
25
|
Shevchenko A, Wilm M, Vorm O and Mann M:
Mass spectrometric sequencing of proteins silver-stained
polyacrylamide gels. Anal Chem. 68:850–858. 1996. View Article : Google Scholar : PubMed/NCBI
|
26
|
Sugimura J, Tamura G, Suzuki Y and Fujioka
T: Allelic loss on chromosomes 3p, 5q and 17p in renal cell
carcinomas. Pathol Int. 47:79–83. 1997. View Article : Google Scholar : PubMed/NCBI
|
27
|
Siu KW, DeSouza LV, Scorilas A, Romaschin
AD, Honey RJ, Stewart R, Pace K, Youssef Y, Chow TF and Yousef GM:
Differential protein expressions in renal cell carcinoma: New
biomarker discovery by mass spectrometry. J Proteome Res.
8:3797–3807. 2009. View Article : Google Scholar : PubMed/NCBI
|
28
|
Cohan CS, Welnhofer EA, Zhao L, Matsumura
F and Yamashiro S: Role of the actin bundling protein fascin in
growth cone morphogenesis: Localization in filopodia and
lamellipodia. Cell Motil Cytoskeleton. 48:109–120. 2001. View Article : Google Scholar : PubMed/NCBI
|
29
|
Sarto C, Marocchi A, Sanchez JC, Giannone
D, Frutiger S, Golaz O, Wilkins MR, Doro G, Cappellano F, Hughes G,
et al: Renal cell carcinoma and normal kidney protein expression.
Electrophoresis. 18:599–604. 1997. View Article : Google Scholar : PubMed/NCBI
|
30
|
Atkins D, Lichtenfels R and Seliger B:
Heat shock proteins in renal cell carcinomas. Contrib Nephrol.
148:35–56. 2005. View Article : Google Scholar : PubMed/NCBI
|
31
|
Oizumi S, Strbo N, Pahwa S, Deyev V and
Podack ER: Molecular and cellular requirements for enhanced antigen
cross-presentation to CD8 cytotoxic T lymphocytes. J Immunol.
179:2310–2317. 2007. View Article : Google Scholar : PubMed/NCBI
|
32
|
Chen M, Ye Y, Yang H, Tamboli P, Matin S,
Tannir NM, Wood CG, Gu J and Wu X: Genome-wide profiling of
chromosomal alterations in renal cell carcinoma using high-density
single nucleotide polymorphism arrays. Int J Cancer. 125:2342–2348.
2009. View Article : Google Scholar : PubMed/NCBI
|
33
|
Seliger B, Lichtenfels R and Kellner R:
Detection of renal cell carcinoma-associated markers via proteome-
and other ‘ome’-based analyses. Brief Funct Genomics Proteomics.
2:194–212. 2003. View Article : Google Scholar
|
34
|
Perego RA, Bianchi C, Corizzato M, Eroini
B, Torsello B, Valsecchi C, Di Fonzo A, Cordani N, Favini P,
Ferrero S, et al: Primary cell cultures arising from normal kidney
and renal cell carcinoma retain the proteomic profile of
corresponding tissues. J Proteome Res. 4:1503–1510. 2005.
View Article : Google Scholar : PubMed/NCBI
|
35
|
Craven RA, Stanley AJ, Hanrahan S, Dods J,
Unwin R, Totty N, Harnden P, Eardley I, Selby PJ and Banks RE:
Proteomic analysis of primary cell lines identifies protein changes
present in renal cell carcinoma. Proteomics. 6:2853–2864. 2006.
View Article : Google Scholar : PubMed/NCBI
|
36
|
Nakamura K, Yoshikawa K, Yamada Y, Saga S,
Aoki S, Taki T, Tobiume M, Shimazui T, Akaza H and Honda N:
Differential profiling analysis of proteins involved in
anti-proliferative effect of interferon-alpha on renal cell
carcinoma cell lines by protein biochip technology. Int J Oncol.
28:965–970. 2006.PubMed/NCBI
|
37
|
Hwa JS, Park HJ, Jung JH, Kam SC, Park HC,
Kim CW, Kang KR, Hyun JS and Chung KH: Identification of proteins
differentially expressed in the conventional renal cell carcinoma
by proteomic analysis. J Korean Med Sci. 20:450–455. 2005.
View Article : Google Scholar : PubMed/NCBI
|
38
|
Atrih A, Mudaliar MAV, Zakikhani P, Lamont
DJ, Huang JT-J, Bray SE, Barton G, Fleming S and Nabi G:
Quantitative proteomics in resected renal cancer tissue for
biomarker discovery and profiling. Br J Cancer. 110:1622–1633.
2014. View Article : Google Scholar : PubMed/NCBI
|